MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - November 02, 2011) -
MorphoSys AG /
MorphoSys and Shionogi Agree Three-Year Extension of Research Partnership
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
has expanded its current licence agreement withShionogi & Co., Ltd., Osaka,
Japan. The expanded agreement covers the use of MorphoSys's HuCAL antibody
technology and additional proprietary technology modules for research in drug
discovery for three additional years and will be run by the company's AbD
Serotec unit. Under the terms of the agreement, Shionogi will continue to have
the right to use MorphoSys's patented antibody library HuCAL PLATINUM for
research purposes at one of its research sites. MorphoSys will receive annual
user fees from Shionogi for access to the technologies. Further financial
details were not disclosed.
"We are very pleased with Shionogi's decision to continue using our HuCAL
antibody technology in drug discovery. Their long-term commitment to HuCAL as
research tool proves the clear scientific and commercial potential the HuCAL
technology has beyond acting as a source of therapeutic antibodies," commented
Dieter Feger, Senior Vice President and Head of AbD Serotec.
MorphoSys and Shionogi signed a first license agreement on the use of
MorphoSys's HuCAL technology in September 2005.
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, arYla®,
RapMAT® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
--- End of Message ---
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE